About: Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.81 (-6.33%)
EVAX NASDAQ Evaxion Biotech AS
Evaxion Biotech AS share price
EVAX price activity
Last Price
$2.800
Change (24hr)
-0.20 USD (-6.74%)
Volume
103.51K
Volume (4w avg)
-
Open
$2.98
Day Range
$2.80 - $2.98
Previous Close
$3.00
Last Trade
13 Oct, 6:29 pm GMT+0
Delayed
13 Oct, 6:29 pm GMT+0
EVAX price performance
Delayed
13 Oct, 6:29 pm GMT+0
EVAX Market Signals